Viewing data from:

DICLOFENAC POTASSIUM

ANDA

DICLOFENAC POTASSIUM | A075152 | WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Diclofenac Potassium (2023)

Total Spending

$43.0M

Total Claims

334,221

Beneficiaries

147,980

Avg Cost/Unit

$1.79

Spending Trend

$4.3M(2019)→$9.5M(2020)→$15.3M(2021)→$40.3M(2022)→$43.0M(2023)

YoY Change:+12.8%

5yr CAGR:+21.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain7 active DMFs4 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

YUNG ZIP CHEMICAL IND CO LTDDICLOFENAC POTASSIUM

DMF 108311994

OLON SPADICLOFENAC POTASSIUM

DMF 112671994

SYN-TECH CHEM AND PHARM CO LTDDICLOFENAC POTASSIUM USP

DMF 126561997

DIPHARMA FRANCIS SRLDICLOFENAC POTASSIUM

DMF 130451998

UNIQUE CHEMICALSDICLOFENAC POTASSIUM USP

DMF 150742000

AMOLI ORGANICS PRIVATE LTDDICLOFENAC POTASSIUM USP

DMF 230282009

HENAN DONGTAI PHARM CO LTDDICLOFENAC POTASSIUM

DMF 305152016

CHENG FONG CHEMICAL CO LTDInactiveDICLOFENAC POTASSIUM

DMF 119901996

ESTEVE QUIMICA SAInactiveDICLOFENAC POTASSIUM

DMF 120211996

FARCHEMIA SRLInactiveDICLOFENAC POTASSIUM

DMF 122171996

CAMBREX PROFARMACO CORK LTDInactiveDICLOFENAC POTASSIUM

DMF 139341999

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Nov 27, 1998	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 27, 1998

No patent or exclusivity listings for this strength.